Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Get updates on Theralase Technologies Inc. delivered in your email.

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Paper by Dr. McFarland

View:

Post by Eoganacht on Oct 25, 2024 11:10am

New Paper by Dr. McFarland

Dr. McFarland and team are now working on Iridium based photosensitizers which work in low oxygen environments.They used red, green and blue light to acivate the 5 new PSs in melanoma and breast cancer cell lines.

Hypoxia-Active Iridium(III) Bis-terpyridine Complexes Bearing Oligothienyl Substituents: Synthesis, Photophysics, and Phototoxicity toward Cancer Cells

October 23, 2024

Xinyang Sun, Houston D. Cole, Ge Shi, Victoria Oas, Alisher Talgatov, Colin G. Cameron, Svetlana Kilina, Sherri A. McFarland, Wenfang Sun

256

Comment

Comment by Gman620 on Oct 25, 2024 11:37am

Summarized by Chatgpt: Researchers created and studied five new iridium complexes that can be activated by light, focusing on their potential to treat cancer. These complexes have different structures that include thienyl units, which affect how they absorb and emit light. They tested how well these complexes worked against various melanoma and breast cancer cell lines in both normal oxygen ...more

196

Comment

Theralase Technologies Inc.

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

FACT SHEET

The Watchlist

< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!

Sign In

Send my password